The FDA approved Nov. 18 Pfizer's drug, Abrilada, a biosimilar to AbbVie's blockbuster rheumatoid arthritis drug, Humira.
Abrilada's approval brings the total number of FDA-approved biosimilars to 25.
Abrilada is designed to treat certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.
Pfizer said it expects to make Abrilada available for patients in 2023.
Read the full news release here.